The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Niemann-Pick Disease (NPD) Market Between 2026 And 2030?
The niemann-pick disease (npd) market has experienced significant expansion in recent years. It is anticipated to grow from $1.07 billion in 2025 to $1.19 billion in 2026, progressing at a compound annual growth rate (CAGR) of 11.1%. Historically, the growth can be attributed to elements such as limited treatment availability, low disease awareness, delayed diagnosis rates, a reliance on symptomatic management, and high treatment costs.
The Niemann-Pick Disease (NPD) market size is projected to experience substantial growth in the upcoming years. It is expected to reach $1.79 billion by 2030, showing a compound annual growth rate (CAGR) of 10.8%. This expansion in the forecast period is attributable to increased funding for rare diseases, progress in gene therapy research, the extension of newborn screening programs, rising healthcare spending, and supportive regulatory frameworks. Key trends for the forecast period include a growing emphasis on early genetic screening, the expansion of orphan drug development, an increase in patient advocacy and awareness initiatives, the advancement of enzyme replacement and substrate reduction therapies, and enhanced multidisciplinary approaches to disease management.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23457&type=smp
Which Primary Drivers Are Impacting The Niemann-Pick Disease (NPD) Market Growth?
The increasing use of gene therapy is anticipated to drive expansion in the niemann-pick disease (NPD) market moving ahead. This medical approach focuses on altering or adjusting an individual’s genes to address or avert illnesses. Its prevalence is increasing, driven by developments in genetic engineering which allow for accurate and impactful gene alterations, leading to better results for genetic conditions. For niemann-pick disease (NPD), gene therapy offers a treatment by addressing the fundamental genetic mutations, with the goal of rectifying the enzyme shortages responsible for the condition and enhancing cellular performance. As an example, the American Society of Gene and Cell Therapy, a US-based group dedicated to gene and cell therapy, reported in January 2024 that the quantity of gene therapies in Phase III trials saw a 10% increase during the fourth quarter of 2023 compared to the preceding quarter. This marked the initial rise observed since the third quarter of 2022. Consequently, the expanding acceptance of gene therapy is fueling the expansion of the niemann-pick disease (NPD) market.
What Are The Different Segment Types In The Niemann-Pick Disease (NPD) Market Segment Breakdown?
The niemann-pick disease (npd) market covered in this report is segmented –
1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C
2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types
3) By Route Of Administration: Oral, Intravenous, Subcutaneous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder
2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder
3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease
Which Trends Are Shaping Growth In The Niemann-Pick Disease (NPD) Market?
Leading companies within the niemann-pick disease (NPD) market are concentrating on developing advanced treatments, such as combination therapy, to boost efficacy and improve patient outcomes. This approach involves administering two or more therapeutic agents or treatment strategies to address a disease or medical condition. The method aims to enhance effectiveness and minimize resistance to single-agent therapy (monotherapy). For instance, in September 2024, Zevra Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for MIPLYFFA, in combination with miglustat, for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in both adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) functions by enhancing the production of heat shock proteins (HSPs), which assist in clearing toxic lipid buildup and protecting neurons from damage. Concurrently, miglustat inhibits glucosylceramide synthase, thereby reducing lipid accumulation. Together, these two therapies help slow the progression of neurological decline in NPC patients.
Who Are The Well-Known Companies In The Niemann-Pick Disease (NPD) Market?
Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children’s Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.
Get The Full Niemann-Pick Disease (NPD) Market Report:
https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report
Which Region Accounts For The Largest Portion Of The Niemann-Pick Disease (NPD) Market?
North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the niemann-pick disease (npd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Niemann-Pick Disease (NPD) Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/niemann-pick-disease-npd-global-market-report
Browse Through More Reports Similar to the Global Niemann-Pick Disease (NPD) Market 2026, By The Business Research Company
Oncology Drugs Market
https://www.thebusinessresearchcompany.com/report/oncology-drugs-market
Community Oncology Services Market Report
https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report
Oncology Companion Diagnostics Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model